VivoSeq
Other

Hyperphosphatemia

27

Pipeline Programs↗

6

Active Trials↗

18

Companies Involved↗

Hyperphosphatemia is an emerging landscape with 27 programs across 18 companies. The most active players are Astellas, R1 Therapeutics, Shanghai Alebund Pharmaceuticals Limited. 7 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

97/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Astellas logo

Astellas

2 programs

Phase 1R

R1 Therapeutics

3 programs

Phase 2S

Shanghai Alebund Pharmaceuticals Limited

1 program

Phase 2M

Metro International Biotech, LLC

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

40

clinical trials

Completed29 · 73%
Recruiting5 · 13%
Unknown status4 · 10%
Terminated1 · 3%
Enrolling by invitation1 · 3%

Clinical Trials

Trial Activity

40 trials

A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
Recruiting·TTaisho Pharmaceutical Co., Ltd.·Phase 3·NCT07285304·300 enrolled
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
Recruiting·AAlebund Pharmaceuticals·Phase 3·NCT06933472·264 enrolled
A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders
Recruiting·TTaisho Pharmaceutical Co., Ltd.·Phase 3·NCT07285291·100 enrolled
Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
Recruiting·JJemincare·Phase 2·NCT06664125·50 enrolled
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Serum Phosphate Lowering Effect of Fixed Dose AP306 in Participants With Hyperphosphatemia Receiving Maintenance Hemodialysis
Recruiting·AAlebund Pharmaceuticals·Phase 2·NCT06712654·168 enrolled
Study the Effect of Niacin on Lipoprotein (a) Concentration and Hyperphosphatemia in Hemodialysis Patients
Enrolling by invitation·—·Phase 2/3·NCT06406140·50 enrolled
Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan
Completed·Astellas logoAstellas·Phase 1·NCT02510274·24 enrolled
A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia
Completed·Tanabe Pharma Corporation logoTanabe Pharma Corporation·Phase 3·NCT00416520·336 enrolled
A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
Completed·AArdelyx·Phase 3·NCT03427125·1,559 enrolled
A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders
Completed·TTaisho Pharmaceutical Co., Ltd.·Phase 2·NCT06745518·62 enrolled
Nicotinamide in Hemodialysis Patients With Hyperphosphatemia
Completed·MMedice Arzneimittel Pütter GmbH & Co KG·Phase 2·NCT01200784·252 enrolled
Individualized Treatment of Hyperphosphatemia in Maintenance Hemodialysis Patients
Completed·—·Phase 3·NCT03861247·123 enrolled
A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients
Completed·AAlebund Pharmaceuticals·Phase 2·NCT05764590·55 enrolled
Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
Completed·Kyowa Kirin Co., Ltd. logoKyowa Kirin Co., Ltd.·Phase 3·NCT04766398·169 enrolled
A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Completed·KKissei Pharmaceutical Co., Ltd.·Phase 3·NCT01833494·161 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)